Latest news with #Shareholders'Meeting
Yahoo
22-05-2025
- Automotive
- Yahoo
Valeo Shareholders' Meeting 2025
PRESS RELEASE Valeo Shareholders' Meeting 2025 May 22, 2025 – Paris, France – Valeo's Shareholders' Meeting was held today. The meeting was chaired by Gilles Michel, Chairman of the Board of Directors. All the resolutions were adopted. The shareholders approved the financial statements for the year ended December 31, 2024 as well as a dividend distribution of 0.42 euro per share. The ex-dividend date is set at May 26, 2025, and the record date at May 27, 2025. The dividend will be paid on May 28, 2025. The Shareholders' Meeting approved the renewal of the term of office of Christophe Périllat as a director for a period of four years. The Board of Directors, which met following the Shareholders' Meeting, unanimously reappointed Christophe Périllat as Chief Executive Officer for the duration of this term, thereby reaffirming its full support for the continued implementation of the Group's strategy. The Shareholders' Meeting also renewed the term of office of Mari-Noëlle Jégo-Laveissière and Véronique Weill as directors for a period of four years, and appointed Gilles Le Borgne as a director, for the same duration, with effect as from January 1st, 2026. Alexandre Dayon's term of office having expired at the end of the Shareholders' Meeting, the Chairman of the Board reiterated, on behalf of the Board, his gratitude for his remarkable commitment to the Board of Directors and its specialized Committees. The Board of Directors therefore comprises (i) at the end of the Shareholders' Meeting, 14 members, including 90.91% of independent directors and 45.45% of women (excluding employee directors) and (ii) as from January 1, 2026 (beginning of Gilles Le Borgne's term of office as a director), 15 directors, including 91.67% of independent directors and 41.67% of women (excluding employee directors). The Shareholders' Meeting approved the compensation paid or granted to directors and executive corporate officers for the 2024 financial year (ex post votes) as well as the compensation policies applicable to directors and executive corporate officers for the 2025 financial year (ex ante votes). In addition, the shareholders renewed the authorizations and financial delegations granted to the Board of Directors to carry out share buybacks and to issue shares and securities. Finally, the articles of association of the company have been amended to incorporate the changes introduced by the Attractiveness Law regarding the decisions of the Board of Directors. About Valeo Valeo is a technology company and partner to all automakers and new mobility players worldwide. Valeo innovates to make mobility safer, smarter and more sustainable. Valeo enjoys technological and industrial leadership in electrification, driving assistance systems, reinvention of the interior experience and lighting everywhere. These four areas, vital to the transformation of mobility, are the Group's growth drivers. Valeo in figures: 21.5 billion euros in sales in 2024 | 106,100 employees, 28 countries, 155 plants, 64 research and development centers and 19 distribution platforms at February 28, 2025. Valeo is listed on the Paris Stock Exchange Learn more at Media ContactsDora Khosrof | +33 7 61 52 82 75Caroline De Gezelle | + 33 7 62 44 17 Investor Relations+33 1 40 55 37 Attachment PR_Valeo Shareholders' Meeting 2025
Yahoo
20-05-2025
- Business
- Yahoo
BIC: Combined Shareholders' Meeting and Board of Directors of Société BIC of May 20th, 2025
Combined Shareholders' Meeting and Board of Directors of Société BIC of May 20th, 2025 Nomination of Edouard Bich as Director and Non-Executive Chair of the Board Renewal of Gonzalve Bich as Director and Chief Executive Officer Nomination of Esther Gaide as Lead Independent Director, Chair of the Audit Committee and member of the Remuneration CommitteeDistribution of ordinary dividend of 3,08 euros per share Clichy, France, May 20th, 2025 – The Combined Shareholders' Meeting of Société BIC was held on Tuesday, May 20th, 2025, at the Cloud Business Center in Paris and was broadcast in live. A replay of the event, as well as the presentations, are available on the BIC website. It was chaired by Candace Matthews, Chair of the Nominations, Governance and CSR Committee, in the presence of Gonzalve Bich, Chief Executive Officer. All resolutions were adopted by the Combined Shareholders' Meeting, including: the approval of the statutory accounts and consolidated accounts for the fiscal year 2024; the payment of an ordinary dividend of €3.08 per share; the renewal of the mandate of Gonzalve Bich as Director; the nomination of Edouard Bich as Director; the nomination of Esther Gaide as Independent Director; the remuneration of the Corporate Officers for the fiscal year 2024; the remuneration policy for the Corporate Officers for the fiscal year 2025; the authorization to be granted to the Board of Directors to trade in the Company's shares (repurchase and cancellation of shares); the delegation of authority to be granted to the Board of Directors to carry out a share capital increase reserved for participants in a company stock ownership plan, with cancellation of preferential subscription rights; the delegation of authority to be granted to the Board of Directors to carry out a share capital increase to remunerate in kind contributions, with cancellation of preferential subscription rights; and the various amendments to the Articles of Association submitted to the vote. The Board of Directors' meeting following the Combined Shareholders' Meeting appointed Edouard Bich as Non-Executive Chair of the Board and renewed Gonzalve Bich's term of office as Chief Executive Officer. The Board also welcomed Marie-Edmée Vallery-Radot, appointed as permanent representative of Société M.B.D. on the Board of Directors. Finally, the Board of Directors appointed Esther Gaide as Lead Independent Director, Chair of the Audit Committee and member of the Remuneration Committee. Following the appointment of Edouard Bich as Chair of the Board, both the CEO and the Chair are considered as non-independent under French corporate governance guidelines. In light of the Bich family's recent announcement of its intention to hold 6 out of the 10 Board seats (excluding Directors representing the employees), the Board has decided to appoint a Lead Independent Director. This appointment will strengthen Société BIC's governance structure by preventing any potential conflicts of interest, and preserving the interests of minority shareholders, complying with the recommendations of the AFEP-MEDEF Corporate Governance Code. Edouard Bich – Non-Executive Chair Managing Director of Société M.B.D., permanent representative in Société BIC's Board of Directors and Audit Committee since 2006 Worked in the Finance Department of Procter and Gamble in France for 8 years Formerly manager of Platypus Capital SPRL in Belgium and member of the Supervisory Committee of Stockage Plus SAS France Gonzalve Bich – Director and CEO Director and CEO of Société BIC since May 2018 Executive Vice-President and Chief Operating Officer from June 2016 to May 2018 Chief Operating Officer, responsible for the Group Consumer Products business, Human Resources and Information Technology from January 2017 to May 2018 Joined BIC in 2003, where he held various sales positions in Europe and Asia, in the field of Human Resources, and Marketing Esther Gaide – Independent Director, Chair of the Audit Committee, member of the Remuneration Committee and Lead Independent Director Director of several Board of Directors such as Iliad, Forvia or Evoriel Chief Finance Officer of Elior until April 2023 More than 30 years of experience in finance in several international companies such as Bolloré, Havas and Technicolor In-depth knowledge of M&A, investors relations and financial process optimization Marie-Edmée Vallery-Radot - Permanent representative of Société M.B.D. Chief Operating Officer for Société M.B.D. From 2016 to 2024: BIC Group – team member of the Commercial and Finance Departments From 2011 to 2016: LVMH Group – retail team *** Contacts Brice ParisVP Investor Relations +33 6 42 87 54 Investor Bethridge ToovellVP Group Communications +1 917 821 Isabelle de Segonzac Image 7, Press Relations +33 6 89 87 61 39isegonzac@ Agenda All dates are to be confirmed H1 2025 results July 30th, 2025 Q3 2025 nets sales October 28th, 2025 About BIC BIC is a world leader in stationery, lighters, and shavers. Its vision: to bring simplicity and joy to everyday life. For 80 years, BIC's commitment to providing high-quality, affordable, and reliable products has made BIC a symbol of reliability and innovation. Present in more than 160 countries and with more than 13,000 employees worldwide, BIC brings together iconic brands and products such as BIC® 4-Colors™, BodyMark®, Cello®, Cristal®, Inkbox®, BIC Kids®, Lucky™, Rocketbook®, Tattly®, Tipp-Ex®, Wite-Out®, Djeep®, EZ Load™, EZ Reach®, BIC® Flex™, Soleil®, Tangle Teezer®, and many others. Listed on Euronext Paris and included in the SBF 120 and CAC Mid 60 indices, BIC is also recognized for its unwavering commitment to sustainability and education. To learn more, visit and to discover the full range of BIC products, visit Follow BIC on LinkedIn, Instagram, YouTube and TikTok. Attachment BIC_CP_Post AGM_20MAY25 ENGSign in to access your portfolio
Yahoo
12-05-2025
- Business
- Yahoo
Rexel: Disclosure of trading in own shares from May 5 to May 9, 2025
RELEASE DISCLOSURE OF TRADING IN OWN SHARES FROM MAY 5 TO MAY 9, 2025 In accordance with the authorization granted by the Shareholders' Meeting in order to trade in own shares and pursuant to applicable law on share repurchases, Rexel declares the following purchases of its own shares from May 5 to May 9, 2025: Name of the issuer Identity code of the issuer (Legal Entity Identifier) Day of transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) REXEL 969500N6AVPA51648T62 05/05/2025 FR0010451203 59 783 24,6838 XPAR REXEL 969500N6AVPA51648T62 06/05/2025 FR0010451203 40 000 24,5436 XPAR REXEL 969500N6AVPA51648T63 07/05/2025 FR0010451204 40 000 24,5744 XPAR REXEL 969500N6AVPA51648T62 08/05/2027 FR0010451203 36 000 24,83914 XPAR REXEL 969500N6AVPA51648T62 09/05/2027 FR0010451203 34 925 25,12385 XPAR TOTAL 210 708 24,7359 The detailed reporting is available: - on Rexel's website: in Investors/Regulated information/Share buyback program section- or by clicking on the following link: program/weekly-share-buyback-programs/ Attachment Disclosure of trading in own shares from May 5 to May 9, 2025Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-04-2025
- Business
- Yahoo
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
Information relating to the holding of the Combined Shareholders' Meeting of 21 May 2025 of Ipsen FRANCE, 30 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Shareholders of the Company are invited to participate in the Combined Shareholders' Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Wednesday 21 May 2025 at 3:00 p.m. (Paris time) at the Salons de l'Hôtel des Arts et Métiers, 9 bis avenue d'Iéna, 75116 Paris. The preliminary notice of the Meeting ('avis de réunion') was published in the Bulletin des Annonces Légales Obligatoires (BALO) of 11 April 2025 and the notice of Meeting ('avis de convocation') was published in the BALO on 30 April 2025. These documents, as well as the Convening notice (including the agenda, the draft resolutions and the conditions regarding attendance and vote), are also available on Ipsen's website at the following address: under the Investors / Regulated Information / Shareholders Meeting section. Documents and information relating to this Meeting are made available to shareholders under the legal and regulatory conditions in force. The Shareholders will be asked to approve in particular the following resolutions: The payment of a dividend of €1.40 per share for the 2024 financial year, the ex-date being set on 4 June 2025 and the dividend payment on 6 June 2025; The renewals of the terms of office of Mr. David LOEW, Mr. Antoine FLOCHEL, Mrs. Margaret LIU and Mrs. Karen WITTS as Directors for a term of 4 years, maintaining the independence Directors' rate within the Board of Directors at a third in accordance with the Afep-Medef Code and each gender's proportion at more than 40% in accordance with the law (Directors representing the employees being not taken into account in these rates). In accordance with applicable regulatory provisions: Registered shareholders may, up to the fifth day (inclusive) before the Meeting, request from the Company to send these documents, where appropriate at his/her express request by electronic means. For holders of bearer shares, the exercise of this right is subject to the presentation of a shareholding certificate (attestation de participation) in the bearer securities accounts managed by the authorized intermediary. Any shareholder may consult these documents at the Company's headquarters. ENDS About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit Ipsen contacts Investors Khalid DEOJEE | + 33 6 66 01 95 26 | Media Sally BAIN | + 1 857 320 0517 | Anne LIONTAS | + 33 7 67 34 72 96 | Disclaimers and/or Forward-Looking Statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on Attachment Documents availability - 2025 Ipsen Combined Shareholder's MeetingSign in to access your portfolio
Business Wire
25-04-2025
- Business
- Business Wire
Verallia: General Shareholders' Meeting Held on April 25 th, 2025
PARIS--(BUSINESS WIRE)--Regulatory News: The annual General Shareholders' Meeting of Verallia (Paris:VRLA) (the 'Company') was held on 25 April 2025 under the chairmanship of Michel Giannuzzi, Chairman of the Board of Directors. The meeting was held in the presence of Patrice Lucas, Chief Executive Officer, Cécile Tandeau de Marsac, Chairwoman of the Compensation Committee and the Nomination Committee, Nathalie Delbreuve, Chief Financial Officer, Wendy Kool-Foulon, CSR Director & General Counsel, as well as the Auditors of the Company. Kaon V and Bpifrance Participations, designated among the shareholders holding the greatest number of voting rights as at the date of the convening notice, acted as ' scrutateurs ' of the Meeting. With a quorum representing 81.20% of the shares of the Company, the Shareholders' General Meeting adopted all the resolutions submitted to its vote. The shareholders have notably approved the statutory and consolidated financial statements for the financial year which ended on 31 December 2024, as well as the distribution of a dividend of €1.70 per share, to be fully paid in cash. Such dividend will be paid on 15 May 2025. Furthermore, the General Shareholders' Meeting approved the renewal of the terms of office of Cécile Tandeau de Marsac and of the representatives of Brasil Warrant Administração de Bens e Empresas S.A. (BWSA) and Bpifrance Investissement as Directors. Additionally, they also renewed the terms of office of BM&A as joint principal statutory auditor responsible for auditing the Company's annual and consolidated financial statements and; as sustainability auditor responsible for verifying information related to sustainability, for a period of six (6) years, i.e. until the end of the general shareholders' meeting to be held in 2031 to vote on the financial statements for the year ended on 31 December 2030. The presentation, the audio-visual rebroadcast and the detailed results of the votes of the General Shareholders' Meeting are available on Verallia's website ( in the Investors section, sub-sections Regulated Information and General Shareholders' Meetings. About Verallia At Verallia, our purpose is to re-imagine glass for a sustainable future. We want to redefine how glass is produced, reused and recycled, to make it the world's most sustainable packaging material. We work together with our customers, suppliers and other partners across the value chain to develop new, beneficial and sustainable solutions for all. With almost 11,000 employees and 35 glass production facilities in 12 countries, we are the European leader and world's third-largest producer of glass packaging for beverages and food products. We offer innovative, customised and environmentally friendly solutions to over 10,000 businesses worldwide. Verallia produced more than 16 billion glass bottles and jars and recorded revenue of €3.5 billion in 2024. Verallia's CSR strategy has been awarded the Ecovadis Platinum Medal, placing the Group in the top 1% of companies assessed by Ecovadis. Our CO2 emissions reduction target of -46% on scopes 1 and 2 between 2019 and 2030 has been validated by SBTi (Science Based Targets Initiative). It is in line with the trajectory of limiting global warming to 1.5° C set by the Paris Agreement. Verallia is listed on compartment A of the regulated market of Euronext Paris (Ticker: VRLA – ISIN: FR0013447729) and trades on the following indices: CAC SBT 1.5°, STOXX600, SBF 120, CAC Mid 60, CAC Mid & Small and CAC All-Tradable.
